- XORTX Therapeutics (XRX) has filed a new provisional patent application with the US Patent Office
- The patent filing refers to observations made in 2020 and 2021 regarding COVID-19 and why some individuals are at greater risk than others
- Acute kidney injury has been identified as an independent risk factor for patients’ in-hospital mortality due to COVID-19
- XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for individuals most susceptible to viral and bacterial infection
- XORTX Therapeutics (XRX) is unchanged, trading at C$0.225 per share at 11:30 am EST
XORTX Therapeutics (XRX) has filed a new provisional patent application with the US Patent Office.
Studies of coronavirus infections show that SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury, proteinuria and hematuria.
Acute kidney injury (“AKI”) has been identified as an independent risk factor for patients’ in-hospital mortality due to COVID-19 as well as other coronavirus infections.
Dr. Allen Davidoff, President and CEO of XORTX stated,
“This new patent filing builds upon new and novel observations made in 2020 and 2021 regarding COVID-19 infection and why some individuals are at much greater risk than others. This patent aligns with the view that COVID-19 is likely to become endemic and the prediction that on a yearly basis millions of individuals worldwide will remain at risk.
XORTX continues to focus on developing leading therapies to treat and protect individuals most susceptible to acute harm to a variety of body systems associated with viral and bacterial infection through our first-in-class programs.”
The focus of the patent is based on clinical data from XORTX scientific partners highlights the importance of addressing aberrant purine metabolism combined with hyperuricemia in patients most at risk to severe COVID-19 outcome.
Since the advent of COVID-19 and during 2020, accumulating evidence suggests that individuals most at risk for more severe health consequences have a higher incidence of hyperuricemia and endothelial dysfunction.
XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development:
- XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- XRx-101 for Coronavirus / COVID-19 infection
- XRx-221 is a clinical-stage program for Type 2 Diabetic Nephropathy (T2DN).
XORTX is working to advance its clinical development-stage products that target xanthine oxidase to inhibit the production of uric acid.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing therapies to treat and protect individuals most susceptible to viral and bacterial infection
XORTX Therapeutics (XRX) is unchanged, trading at C$0.225 per share at 11:30 am EST.
